Special Issue "Tuberculosis Vaccines"

Quicklinks

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 October 2013)

Special Issue Editors

Guest Editor
Prof. Dr. Chinnaswamy Jagannath
Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, 6400 Fannin Street, MSB 2.200, Houston, TX 77030, USA
Website: http://www.uthouston.edu/gsbs/faculty/faculty-directory/faculty-profiles.htm?id=1346243
E-Mail: Chinnaswamy.Jagannath@uth.tmc.edu
Phone: +1 713 500 5353
Interests: vaccines for tuberculosis; TLR signaling and adjuvants; Th1 immunity and T cells; Dendritic cells and macrophages-pathogen survival

Guest Editor
Prof. Dr. Abu Salim Mustafa
Department of Microbiology, Faculty of Medicine, Kuwait University PO Box 24923, Safat 13110, Kuwait
Website: http://www.hsc.edu.kw/services/staff_PDF/abusalim.pdf
E-Mail: abusalim@hsc.edu.kw
Phone: +965 24896505
Fax: +965 25332719
Interests: Tuberculosis; vaccines; immunodiagnosis; immuno-pathogenesis

Special Issue Information

Dear Colleagues,

Tuberculosis is a major health problem of global concern. According to estimates from the World Health Organization, one-third of the world population is infected with Mycobacterium tuberculosis, over 9 million people develop active disease and 2 million people die of tuberculosis each year. To immunize against tuberculosis, routine vaccination with Mycobacterium bovis BCG is practiced in many countries. Although, BCG vaccine offers some protection against childhood tuberculosis and severe forms of the disease in adults, it has failed to provide consistent protection against pulmonary disease in adults, which is the major manifestation of tuberculosis. Investigators are attempting to develop improved vaccines against tuberculosis by genetic manipulation of BCG, identifying M. tuberculosis auxotroph and protein antigens as subunit vaccines, etc. This special issue on “Tuberculosis Vaccines”  will highlight leading developments in the vaccine technology, including but not limited to, genetically modified BCG, M. tuberculosis-derived vaccines, subunit (proteins/peptide, DNA and recombinant) vaccines, and their validation in animal models. Novel mechanisms of enhancing vaccine efficacy are also welcome including research on adjuvants and biomarkers of protection against tuberculosis. The special issue will be a mix of original research articles, and mini reviews. The main focus of this special issue is to present cutting edge research and recent developments in vaccines, which can prevent tuberculosis in mankind.

We look forward to reading your contributions

Prof. Dr. Chinnaswamy Jagannath
Prof. Dr. Abu Salim Mustafa
Guest Editors

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

Keywords

  • genetically modified BCG
  • M. tuberculosis-derived vaccines
  • subunit and peptide-based vaccines
  • DNA vaccines
  • recombinant-vector based vaccines
  • adjuvants for vaccine delivery
  • biomarkers of protection and novel mechanisms for enhancing vaccine efficacy

Published Papers (4 papers)

by , , , , , , ,  and
Vaccines 2013, 1(1), 34-57; doi:10.3390/vaccines1010034
Received: 26 October 2012; in revised form: 18 December 2012 / Accepted: 5 January 2013 / Published: 11 January 2013
Show/Hide Abstract | PDF Full-text (2512 KB) | HTML Full-text | XML Full-text

by  and
Vaccines 2013, 1(1), 58-76; doi:10.3390/vaccines1010058
Received: 13 December 2012; in revised form: 13 December 2012 / Accepted: 15 January 2013 / Published: 25 January 2013
Show/Hide Abstract | PDF Full-text (447 KB) | HTML Full-text | XML Full-text

by , , , , , , , , , , , , ,  and
Vaccines 2013, 1(2), 120-138; doi:10.3390/vaccines1020120
Received: 28 February 2013; in revised form: 3 April 2013 / Accepted: 8 April 2013 / Published: 16 April 2013
Show/Hide Abstract | Cited by 2 | PDF Full-text (494 KB) | XML Full-text
abstract graphic

by , , , ,  and
Vaccines 2014, 2(2), 463-499; doi:10.3390/vaccines2020463
Received: 13 February 2014; in revised form: 24 April 2014 / Accepted: 6 May 2014 / Published: 16 June 2014
Show/Hide Abstract | PDF Full-text (723 KB) | HTML Full-text | XML Full-text

Last update: 24 January 2013

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert